Black and Hispanic patients with MCC are more likely to have tumors on UV-protected sites, which is associated with better outcomes.

Ixekizumab was more effective for the treatment of mild to moderate psoriasis vs severe psoriasis at most time points through 52 weeks.

Researchers reported findings through week 24 from the ongoing, multicenter, randomized, double-blind, placebo-controlled phase 3b APEX trial. Treatment with guselkumab 100 mg for psoriatic arthritis ...

Researchers assessed treatment patterns and health care resource use among patients with Sjögren disease before vs after diagnosis. Rates of outpatient visits, inpatient visits, emergency department ...

At 48 weeks of baricitinib, most patients (63.2%) achieved significant improvement in the severity of alopecia areata, with decreases seen among various trichoscopic signs from baseline. A real-world ...

Significantly greater proportions of patients with moderate to severe plaque psoriasis who were receiving D-2570 at any dose achieved at least a 75% improvement in Psoriasis Index and Severity scores ...

Researchers assessed changes in psoriatic arthritis disease activity throughout the stages of menopause. Being in perimenopause was significantly associated with higher psoriatic arthritis disease ...